JP2010132668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010132668A5 JP2010132668A5 JP2010000907A JP2010000907A JP2010132668A5 JP 2010132668 A5 JP2010132668 A5 JP 2010132668A5 JP 2010000907 A JP2010000907 A JP 2010000907A JP 2010000907 A JP2010000907 A JP 2010000907A JP 2010132668 A5 JP2010132668 A5 JP 2010132668A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- composition according
- montelukast sodium
- hemisorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims 5
- 229960001951 montelukast sodium Drugs 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010034133 Pathogen resistance Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 238000005384 cross polarization magic-angle spinning Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46294103P | 2003-04-15 | 2003-04-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509926A Division JP2006523699A (ja) | 2003-04-15 | 2004-04-12 | モンテルカストナトリウムの多形形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010132668A JP2010132668A (ja) | 2010-06-17 |
| JP2010132668A5 true JP2010132668A5 (enExample) | 2011-03-17 |
Family
ID=33300016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509926A Pending JP2006523699A (ja) | 2003-04-15 | 2004-04-12 | モンテルカストナトリウムの多形形態 |
| JP2010000907A Withdrawn JP2010132668A (ja) | 2003-04-15 | 2010-01-06 | モンテルカストナトリウムの多形形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509926A Pending JP2006523699A (ja) | 2003-04-15 | 2004-04-12 | モンテルカストナトリウムの多形形態 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7560559B2 (enExample) |
| EP (1) | EP1633357A4 (enExample) |
| JP (2) | JP2006523699A (enExample) |
| CN (1) | CN1852713B (enExample) |
| AU (1) | AU2004229507B2 (enExample) |
| CA (1) | CA2522053C (enExample) |
| WO (1) | WO2004091618A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050187244A1 (en) * | 2004-01-30 | 2005-08-25 | Entire Interest. | Montelukast sodium polymorphs |
| EP1708708A1 (en) * | 2004-01-30 | 2006-10-11 | Teva Pharmaceutical Industries Ltd. | Montelukast free acid polymorphs |
| CA2563776A1 (en) | 2004-04-21 | 2005-11-10 | Teva Pharmaceutical Industries Ltd. | Processes for preparing montelukast sodium |
| US20080146809A1 (en) * | 2004-11-19 | 2008-06-19 | Matrix Laboratories Ltd | Process for the Preparation of Novel Amorphous Montelukast Sodium |
| US7812168B2 (en) | 2005-07-05 | 2010-10-12 | Teva Pharmaceutical Industries Ltd. | Purification of montelukast |
| ES2403067T3 (es) * | 2005-12-13 | 2013-05-13 | Msn Laboratories Limited | Un procedimiento mejorado para la preparación de montelukast y sus sales farmaceúticamente aceptables |
| US8115004B2 (en) * | 2006-11-20 | 2012-02-14 | Msn Laboratories Limited | Process for pure montelukast sodium through pure intermediates as well as amine salts |
| WO2010064257A1 (en) * | 2008-12-01 | 2010-06-10 | Innogent Laboratories Private Limited | Novel intermediates for producing [r-(e)]-1-[[[1-[3-[2-(7- chloro -quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy- methylethyl) phenyl]propyl]thio] methyl] cyclopropaneacetic acid, monosodium salt and process thereof |
| EP2287154A1 (en) | 2009-07-14 | 2011-02-23 | KRKA, D.D., Novo Mesto | Efficient synthesis for the preparation of montelukast |
| WO2011033470A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Crystalline form of montelukast sodium |
| US20110195042A1 (en) * | 2010-02-10 | 2011-08-11 | Thomas Edward Huetter | Compositions, Methods and Kits Useful for Treating a Respiratory Symptom |
| EP2552892A1 (en) | 2010-03-31 | 2013-02-06 | KRKA, D.D., Novo Mesto | Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein |
| KR100990046B1 (ko) | 2010-07-30 | 2010-10-26 | 동국제약 주식회사 | 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법 |
| US8471030B2 (en) | 2010-12-06 | 2013-06-25 | Orochem Technologies Inc. | Purification of montelukast using simulated moving bed |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| CN104055741B (zh) * | 2013-03-18 | 2017-02-15 | 青岛大学 | 一种孟鲁司特钠片剂及其制备方法 |
| CN104649968B (zh) * | 2013-11-25 | 2017-03-15 | 天津汉瑞药业有限公司 | 一种孟鲁司特钠倍半水合物化合物 |
| JP2017503814A (ja) | 2014-01-22 | 2017-02-02 | タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療 |
| CN107049940A (zh) * | 2017-03-10 | 2017-08-18 | 重庆西南医院 | 一种促进孟鲁司特钠经直肠吸收的促进剂及其使用方法 |
| CN107162969A (zh) * | 2017-07-05 | 2017-09-15 | 成都亿知科技有限公司 | 孟鲁司特钠晶体及其制备方法和药物组合物 |
| CN112789037A (zh) | 2018-09-06 | 2021-05-11 | 创新药物筛选有限公司 | 用于治疗哮喘或帕金森病的方法和药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| TW416948B (en) * | 1993-12-28 | 2001-01-01 | Merck & Co Inc | Process for the preparation of leukotriene antagonists |
| US5523477A (en) * | 1995-01-23 | 1996-06-04 | Merck & Co., Inc. | Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid |
| US5869673A (en) * | 1997-02-28 | 1999-02-09 | Merck & Co., Inc. | Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde |
| US5952347A (en) * | 1997-03-13 | 1999-09-14 | Merck & Co., Inc. | Quinoline leukotriene antagonists |
| CN1329505A (zh) * | 1998-10-09 | 2002-01-02 | 先灵公司 | 用于治疗变应性疾病的组合物和方法 |
| AU2002256967A1 (en) * | 2000-10-30 | 2002-09-12 | Schering Corporation | Treating or reducing the risk of cardiovascular disease |
| AU2003209043A1 (en) * | 2002-02-07 | 2003-09-02 | Dr. Reddy's Laboratories Ltd. | Novel anhydrous amorphous forms of montelukast sodium salt |
-
2004
- 2004-04-12 CA CA2522053A patent/CA2522053C/en not_active Expired - Fee Related
- 2004-04-12 AU AU2004229507A patent/AU2004229507B2/en not_active Ceased
- 2004-04-12 JP JP2006509926A patent/JP2006523699A/ja active Pending
- 2004-04-12 EP EP04759442A patent/EP1633357A4/en not_active Withdrawn
- 2004-04-12 WO PCT/US2004/011211 patent/WO2004091618A1/en not_active Ceased
- 2004-04-12 CN CN2004800163215A patent/CN1852713B/zh not_active Expired - Fee Related
- 2004-04-12 US US10/553,069 patent/US7560559B2/en not_active Expired - Fee Related
-
2010
- 2010-01-06 JP JP2010000907A patent/JP2010132668A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010132668A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| JP2012107057A5 (enExample) | ||
| JP2013014622A5 (enExample) | ||
| IL226490A (en) | Pharmaceuticals containing benzensulfonamide compounds are used for the treatment of lupus erythematosus, kidney inflammation due to lupus and rheumatic syndrome | |
| JP2013525444A5 (enExample) | ||
| CL2007002099A1 (es) | Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma. | |
| WO2010094720A3 (en) | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| JP2014500861A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2009545527A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| JP2011105738A5 (enExample) | ||
| IL226853A (en) | Annotations of 3 [(2,1-oxazole-4-yl) methoxy] -8-azabicyclo [1.2.3] octane, processes for their preparation, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of fxr | |
| JP2011006431A5 (enExample) | ||
| JP2011527299A5 (enExample) | ||
| WO2006117300A3 (en) | Crystalline forms of tiotropium bromide | |
| JP2008513510A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2008516004A5 (enExample) | ||
| JP2011515406A5 (enExample) | ||
| Beinat et al. | Structure–activity relationship studies of SEN12333 analogues: determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs |